Revitacare, Acquired by Bloomage Biotech, Achieves Nearly 300 Million RMB in Revenue

6月 26, 2023

In 2017, Bloomage Biotech (SH: 699363), a Chinese leader in hyaluronic acid, acquired the French counterpart Revitacare for a total of 14.275 million euros. This acquisition provided Bloomage Biotech with access to Revitacare’s French research talent, customer resources, distribution networks, and the Cytocare product line. It marked Bloomage Biotech’s first overseas acquisition.
The Cytocare line is familiar to many beauty enthusiasts. In 2018, Cytocare 715 C line, a functional skincare product, entered the Chinese market. Revitacare’s revenue grew nearly fivefold, …